Zydus Lifesciences shares rise nearly 2% on inking exclusive licensing, commercialisation pact with RK Pharma

The stock rose as much as 1.65% to ₹943.85 crore on the National Stock Exchange (NSE). At 2:35 pm, it was trading 1.40% higher at ₹941.50.

The company's market capitalisation stands at ₹94,726.87 crore.

Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA (new drug application) submission and commercialisation of the product in the US, the company said in a regulatory filing.

The product is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals, it added.

"We are delighted to collaborate with RK Pharma to bring this innovative product to patients in the US. This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care," Zydus Lifesciences Managing Director Sharvil Patel said.

RK Pharma Founder and Executive Chairman Ravishanker Kovi said, "Our collaboration with Zydus, a company with robust regulatory expertise and a powerful commercial footprint, ensures that this important therapeutic option reaches patients efficiently, reinforcing our shared mission to improve access to high-quality healthcare in the USA."

The novel product targets a significant commercial opportunity in the US market, with an estimated total addressable market of 6.2 million units, Zydus said, citing IQVIA MAT September 2025 data.

On November 25, the company had received final approval from the United States Food and Drug Administration (USFDA) for blood pressure drug Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg.